Key facts
- It has raised $89.0M; the latest was Later Stage VC ($54.6M) in Feb 2025.
- Notable investors include European Innovation Council, MedTech Innovator, European Union, Brabantse Ontwikkelings Maatschappij, Invest-NL (Investment Company) — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Salvia BioElectronics
- ·The full record, as it builds
Funding rounds
No funding rounds for Salvia BioElectronics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Salvia BioElectronics
Developer of bioelectronic technology designed to assist in the treatment of chronic neurological disease. The company's technology includes smart devices that use mild electrical impulses to influence nerve activity that restores health for people suffering from chronic migraine, enabling patients to access a neurostimulation alternative for drug-refractory migraine.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2017
- Employees
- 49
- Website
- salviabioelectronics.com/
- Ownership
- Privately Held (backing)
Salvia BioElectronics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Salvia BioElectronics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Salvia BioElectronics in its N-PORT filings yet. We sweep new filings monthly.